Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
OBJECTIVE: Therapies that deplete lymphocytes often improve symptoms in patients with otherwise refractory autoimmune disease but may result in long-term lymphopenia, the consequences of which are uncertain. To assess the impact of prolonged lymphopenia on morbidity and mortality, we studied patien...
Main Authors: | Isaacs, J, Greer, S, Sharma, S, Symmons, D, Smith, M, Johnston, J, Waldmann, H, Hale, G, Hazleman, B |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2001
|
Similar Items
-
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.
by: Lorenzi, A, et al.
Published: (2008) -
Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: comment on the article by Isaacs et al - Reply
by: Isaacs, J, et al.
Published: (2002) -
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
by: Isaacs, J, et al.
Published: (2004) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
by: Isaacs, J, et al.
Published: (2005) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
by: Isaacs, J, et al.
Published: (2005)